Inozyme Pharma Inc
(NAS:INZY)
$
4.07
-0.35 (-7.92%)
Market Cap: 273.09 Mil
Enterprise Value: 198.76 Mil
PE Ratio: 0
PB Ratio: 2.68
GF Score: 41/100 
Inozyme Pharma Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023 / 01:30PM GMT
Release Date Price:
$6.1
(+2.35%)
Nalin Tejavibulya
(Trades, Portfolio) LLC - Analyst
Hi. Good morning. My name is Nalin Tejavibulya. I am a member of the biotechnology research team at Jefferies. And it is my pleasure to introduce Doug Treco, CEO of Inozyme. Thank you very much for joining us.
Doug Treco
Inozyme Pharma, Inc. - CEO & Chairman of Board of Directors
Thanks very much, Nalin, and thanks for the organizers for inviting us here today. As Nalin said, I'm Doug Treco, the CEO of Inozyme Pharma, and we're developing an enzyme replacement therapy for a series of rare genetic diseases.
Obviously, we're a public company, so please pay attention. So we are developing enzyme replacement therapy for rare diseases of pathologic mineralization within the body as well as intimal
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers